Status: Recruiting
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).
Participants needed: 64
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Beckley Psytech LimitedUpdated: May 26, 2026Locations: 3
Eligibility criteria
Diagnosed with Major Depressive Disorder. [+5]
Current or history of schizophrenia, psychotic disorder including psychotic depr... [+13]